Life Sciences

Advancements in science and technology continue to foster a favourable environment for innovation across most therapeutic areas within Life Sciences.

Pillar
Quoted equities
Theme
Healthcare innovation
Status
Current investment
Geography
Global, USA
Invested date
2010

Furthermore, pressures facing large Pharma, such as patent cliffs, are likely to result in a pick-up in M&A activity, benefitting Biotech companies. In addition, valuations have meaningfully corrected post the 2021 peak as generalist investors have exited the subsector. This leaves a compelling opportunity set for specialist healthcare investors with capital duration.

In selecting specialist managers to exploit this structural opportunity set, RIT has focused on the following:

  • Managers that marry the science with commercial viability.
  • Managers that are investing in rare and severe disease areas – allowing for truly life-transforming benefits to patients.
  • Managers that can invest across the market cap spectrum – from early stage through to late-stage large Pharma – to enable them to invest in the changing opportunity sets over time.

RIT’s specialist managers satisfy the above criteria and have also demonstrated an ability to identify winners early, with staying power through market cycles resulting in meaningful long-term outperformance against industry benchmarks.